Case Report: Successful treatment of new onset plaque psoriasis with secukinumab in a peritoneal dialysis patient
-
By
-
Junyan Fang
-
Ruolin Li
-
Yingxin Xie
-
Yingli Liu
-
July 8, 2026
-
Clinical Scorecard: Case Study: Effective Management of Newly Developed Plaque Psoriasis with Secukinumab in a Patient Undergoing Peritoneal Dialysis
At a Glance
| Category | Detail |
|---|
| Condition | Plaque Psoriasis |
| Key Mechanisms | Immune-mediated inflammatory skin disorder involving IL-23/Th17 axis dysregulation. |
| Target Population | Patients undergoing peritoneal dialysis with severe psoriasis. |
| Care Setting | Clinical management of psoriasis in patients with chronic kidney disease. |
Key Highlights
- Secukinumab effectively treated severe plaque psoriasis in a patient on peritoneal dialysis.
- The patient achieved complete clearance of psoriatic lesions after 12 months of treatment.
- Initial management included intensified dialysis and topical corticosteroids, which were insufficient.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of psoriasis confirmed through dermatological evaluation and PASI scoring.
Management
- Initiate secukinumab at 300 mg subcutaneously weekly for four weeks, followed by maintenance dosing.
Monitoring & Follow-up
- Monitor PASI scores and patient-reported outcomes for treatment efficacy.
Risks
- Consider potential adverse events and contraindications of systemic therapies in patients with renal impairment.
Patient & Prescribing Data
61-year-old male with ESRD on peritoneal dialysis.
Secukinumab was well tolerated with significant improvement in psoriasis and no adverse events.
Clinical Best Practices
- Consider biologic therapy for severe psoriasis in patients with renal impairment when conventional therapies are contraindicated.
- Regularly assess dialysis adequacy and its impact on psoriasis management.
Related Resources & Content
